Skip to main content

Identification and experimental validation of diagnostic and prognostic genes CX3CR1, PID1 and PTGDS in sepsis and ARDS using bulk and single-cell transcriptomic analysis and machine learning.

Frontiers in immunology2025-01-07PubMed
Total: 68.5Innovation: 7Impact: 6Rigor: 7Citation: 7

Summary

Across multiple public datasets, WGCNA and machine learning converged on CX3CR1, PID1, and PTGDS as shared diagnostic/prognostic genes for sepsis and ARDS, with external validation and experimental confirmation (RT-qPCR, H&E). Immune infiltration and single-cell analyses mapped cell-type specificity and suggested drug candidates.

Key Findings

  • Identified 242 shared DEGs between sepsis and ARDS; modules linked to poor prognosis and ARDS
  • Three key genes (CX3CR1, PID1, PTGDS) selected by WGCNA and ML (LASSO, RF, Boruta) showed high AUCs and external validation
  • Single-cell and immune infiltration analyses mapped gene localization; RT-qPCR and H&E confirmed differential expression in PBMCs and mouse models

Clinical Implications

The three-gene panel could inform diagnostic scoring and prognostic assessment once prospectively validated; predicted drugs offer a starting point for repurposing studies.

Why It Matters

Provides a reproducible, multi-omic framework identifying tractable biomarkers for sepsis–ARDS, enabling risk stratification and hypothesis-driven target discovery.

Limitations

  • Retrospective datasets with potential batch effects; sample sizes per cohort not detailed here
  • Clinical implementation requires prospective validation and standardized assays

Future Directions

Prospective, multicenter validation with standardized platforms; functional studies of CX3CR1, PID1, PTGDS and testing predicted drugs.

Study Information

Study Type
Case-control
Research Domain
Diagnosis
Evidence Level
III - Retrospective case-control analyses with external validation and experimental confirmation
Study Design
OTHER